The ECHELON-2 Trial: Results of a Randomized, Double-Blind, Active-Controlled Phase 3 Study of Brentuximab Vedotin and CHP (A plus CHP) Versus CHOP in the Frontline Treatment of Patients with CD30+Peripheral T-Cell Lymphomas

被引：2

作者：

Horwitz, Steven M. ^{[1
]}

O'Connor, Owen A. ^{[2
]}

Pro, Barbara ^{[3
]}

Illidge, Tim M. ^{[4
]}

Fanale, Michelle A. ^{[5
]}

Advani, Ranjana H. ^{[6
]}

Bartlett, Nancy L. ^{[7
]}

Christensen, Jacob Haaber ^{[8
]}

Morschhauser, Franck ^{[9
]}

Domingo-Domenech, Eva ^{[10
]}

Rossi, Giuseppe ^{[11
]}

Kim, Won Seog ^{[12
]}

Feldman, Tatyana A. ^{[13
]}

Lennard, Anne ^{[14
]}

Belada, David ^{[15
,16
]}

Illes, Arpad ^{[17
]}

Tobinai, Kensei ^{[18
]}

Tsukasaki, Kunihiro ^{[19
]}

Yeh, Su-Peng ^{[20
]}

Shustov, Andrei R. ^{[21
]}

Huettmann, Andreas ^{[22
]}

Savage, Kerry J. ^{[23
,24
]}

Yuen, Sam ^{[25
]}

Zinzani, Pier Luigi ^{[26
]}

Hua, Zhaowei ^{[27
]}

Little, Meredith ^{[27
]}

Rao, Shangbang ^{[28
]}

Woolery, Joseph ^{[28
]}

Manley, Thomas ^{[29
]}

Truemper, Lorenz ^{[30
]}

机构：

[1] Mem Sloan Kettering Canc Ctr, Basking Ridge, NJ USA

[2] Columbia Univ, Med Ctr, New York, NY USA

[3] Northwestern Univ, Dept Med, Feinberg Sch Med, Div Hematol & Oncol, Chicago, IL 60611 USA

[4] Univ Manchester, Christie Hosp NHS Fdn Trust, Manchester Acad Hlth Sci Ctr, Div Canc Sci,Fac Biol Med & Hlth,NIHR Biomed Res, Manchester, Lancs, England

[5] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[6] Stanford Canc Ctr, Blood & Marrow Transplant Program, Stanford, CA USA

[7] Washington Univ, Sch Med, Siteman Canc Ctr, St Louis, MO USA

[8] Odense Univ Hosp, Odense, Denmark

[9] CHRU Lille, Lille, Nord Pas De Cal, France

[10] Inst Catala Oncol, Barcelona, Spain

[11] Azienda Osped Spedali Civili Brescia, Brescia, Italy

[12] Samsung Med Ctr, Seoul, South Korea

[13] Hackensack Univ Med Ctr, Hackensack, NJ USA

[14] Freeman Rd Hosp, Newcastle Upon Tyne, Tyne & Wear, England

[15] Univ Hosp, Dept Internal Med Hematol 4, Hradec Kralove, Czech Republic

[16] Charles Univ Prague, Fac Med, Prague, Czech Republic

[17] Debreceni Egyet, Debrecen, Hungary

[18] Natl Canc Ctr, Tokyo, Japan

[19] Saitama Med Univ, Dept Hematol, Int Med Ctr, Saitama, Japan

[20] China Med Univ Hosp, Taichung, Taiwan

[21] Univ Washington, Med Ctr, Seattle, WA 98195 USA

[22] Univ Klinikum Essen, Essen, Germany

[23] Univ British Columbia, Vancouver, BC, Canada

[24] British Columbia Canc Agcy, Ctr Lymphoid Canc, Dept Med Oncol, Vancouver, BC, Canada

[25] Calvary Mater Newcastle Hosp, Newcastle, NSW, Australia

[26] Univ Bologna, Inst Hematol Seragnoli, Bologna, Italy

[27] Takeda Pharmaceut Int Co, Cambridge, MA USA

[28] Seattle Genet, Bothell, WA USA

[29] Seattle Genet Inc, Bothell, WA USA

[30] Univ Med Gottingen, Gottingen, Germany

来源：

BLOOD | 2018年 / 132卷

关键词：

D O I：

10.1182/blood-2018-99-110563

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

997

引用

页数：5

共 50 条

[21] Four-Year Survival and Durability Results of Brentuximab Vedotin in Combination with CHP in the Frontline Treatment of Patients with CD30-Expressing Peripheral T-Cell Lymphomas
Fanale, Michelle A.
Horwitz, Steven M.
Forero-Torres, Andres
Bartlett, Nancy L.
Advani, Ranjana H.
Pro, Barbara
Chen, Robert W.
Davies, Andrew J.
Illidge, Tim
Uttarwar, Mayur
Huebner, Dirk
Ren, Hong
Shustov, Andrei R.
BLOOD, 2016, 128 (22)
[22] Frontline brentuximab vedotin and CHP (A plus CHP) in patients (pts) with peripheral T-cell lymphoma with less than 10% CD30 expression: Results from the phase 2 SGN35-032 study
Iyer, Swaminathan Padmanabhan
Jagadeesh, Deepa
Domingo-Domenech, Eva
Benedetti, Fabio
Izquierdo, Antonia Rodriguez
Bouabdallah, Krimo
Vitolo, Umberto
Illidge, Tim M.
Liu, Jingmin
Shaikh, Eeman
Horwitz, Steven M.
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[23] Evaluation of the combination of brentuximab vedotin and chemotherapy in peripheral CD30 + T lymphomas: controlled, randomized, double-blind trial
Charlotte, Berthoux
Laure, Farnault
Geoffroy, Venton
HEMATOLOGIE, 2019, 25 (02): : 65 - 65
[24] The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma
Horwitz, S.
O'Connor, O. A.
Pro, B.
Trumper, L.
Iyer, S.
Advani, R.
Bartlett, N. L.
Christensen, J. H.
Morschhauser, F.
Domingo-Domenech, E.
Rossi, G.
Kim, W. S.
Feldman, T.
Menne, T.
Belada, D.
Illes, A.
Tobinai, K.
Tsukasaki, K.
Yeh, S-P
Shustov, A.
Huettmann, A.
Savage, K. J.
Yuen, S.
Zinzani, P. L.
Miao, H.
Bunn, V
Fenton, K.
Fanale, M.
Puhlmann, M.
Illidge, T.
ANNALS OF ONCOLOGY, 2022, 33 (03) : 288 - 298
[25] Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial (vol 393, pg 229, 2019)
Horwitz, S.
O'Connor, O. A.
Pro, B.
LANCET, 2019, 393 (10168): : 228 - 228
[26] BRENTUXIMAB VEDOTIN IN COMBINATION WITH CHP IN PATIENTS (PTS) WITH NEWLY-DIAGNOSED CD30+PERIPHERAL T-CELL LYMPHOMAS (PTCL): 2-YEAR FOLLOW-UP
Fanale, M. A.
Horwitz, S. M.
Forero-Torres, A.
Bartlett, N. L.
Advani, R. H.
Pro, B.
Chen, R. W.
Davies, A.
Illidge, T.
Huebner, D.
Kennedy, D. A.
Shustov, A. R.
ANNALS OF ONCOLOGY, 2014, 25
[27] Brentuximab vedotin in the treatment of relapsed/refractory CD30+peripheral T-cell lymphoma: A FIL phase 2 study
Stefoni, Vittorio
Pellegrini, Cinzia
Argnani, Lisa
Corradini, Paolo
Dodero, Anna
Orsucci, Lorella
Volpetti, Stefano
Zinzani, Pier Luigi
HEMATOLOGICAL ONCOLOGY, 2022, 40 (02) : 307 - 309
[28] ECHELON-2 (NCT01777152), a randomized, double-blind, phase 3 study of brentuximab vedotin plus cyclophosphamide doxorubicin and prednisone versus cyclophosphamide, doxorubicin, vincristine and prednisone in previously untreated patients with CD30-positive peripheral T-cell lymphoma: 5-year results
Illidge, Timothy
Horwitz, Steven M.
O'Connor, Owen A.
Pro, Barbara
Iyer, Swami P.
Advani, Ranjana
Bartlett, Nancy L.
Christensen, Jacob Haaber
Morschhauser, Franck
Domingo-Domenech, Eva
Rossi, Giuseppe
Kim, Won Seog
Feldman, Tatyana A.
Menne, Tobias
Belada, David
Illes, Arpad
Tobinai, Kensei
Tsukasaki, Kunihiro
Yeh, Su-Peng
Huettmann, Andreas
Savage, Kerry J.
Yuen, Sam
Zinzani, Pier Luigi
Miao, Harry
Bunn, Veronica
Fenton, Keenan
Fanale, Michelle A.
Puhlmann, Markus
Truemper, Lorenz
BRITISH JOURNAL OF HAEMATOLOGY, 2021, 193 : 38 - 40
[29] Brentuximab Vedotin in the Front-Line Treatment of Patients With CD30+ Peripheral T-Cell Lymphomas: Results of a Phase I Study
Fanale, Michelle A.
Horwitz, Steven M.
Forero-Torres, Andres
Bartlett, Nancy L.
Advani, Ranjana H.
Pro, Barbara
Chen, Robert W.
Davies, Andrew
Illidge, Tim
Huebner, Dirk
Kennedy, Dana A.
Shustov, Andrei R.
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (28) : 3137 - +
[30] Brentuximab vedotin plus cyclophosphamide, doxorubicin, etoposide, and prednisone followed by brentuximab vedotin consolidation in CD30-positive peripheral T-cell lymphomas: a multicentre, single-arm, phase 2 study
Herrera, Alex F.
Zain, Jasmine
Savage, Kerry J.
Feldman, Tatyana
Brammer, Jonathan E.
Chen, Lu
Puverel, Sandrine
Popplewell, Leslie
Budde, Lihua Elizabeth
Mei, Matthew
Hosing, Chitra
Nair, Ranjit
Leslie, Lori
Daniels, Shari
Peters, Lacolle
Forman, Stephen
Rosen, Steven
Kwak, Larry
Iyer, Swaminathan P.
Haematol, Lancet
LANCET HAEMATOLOGY, 2024, 11 (09): : e671 - e681

← 1 2 3 4 5 →